According to CTI BioPharma 's latest financial reports the company's current revenue (TTM) is $75.76 M. In 2022 the company made a revenue of $53.94 M an increase over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $75.76 M | 40.45% |
2022 | $53.94 M | |
2021 | N/A | |
2020 | N/A | -100% |
2019 | $3.34 M | -87.1% |
2018 | $25.92 M | 3.08% |
2017 | $25.14 M | -56.2% |
2016 | $57.4 M | 256.2% |
2015 | $16.11 M | -73.17% |
2014 | $60.07 M | 73.24% |
2013 | $34.67 M | |
2012 | N/A | |
2011 | N/A | -100% |
2010 | $0.31 M | 298.75% |
2009 | $0.08 M | -99.3% |
2008 | $11.43 M | 8901.57% |
2007 | $0.12 M | 58.75% |
2006 | $0.08 M | -99.5% |
2005 | $16.09 M | -45.62% |
2004 | $29.59 M | 19.5% |
2003 | $24.76 M | 46.57% |
2002 | $16.89 M | 170.94% |
2001 | $6.23 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novartis NVS | $49.92 B | 65,789.74% | ๐จ๐ญ Switzerland |
Eli Lilly LLY | $35.93 B | 47,323.22% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 37,105.19% | ๐บ๐ธ USA |
Baxter BAX | $14.89 B | 19,554.48% | ๐บ๐ธ USA |
Incyte INCY | $3.76 B | 4,872.83% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 59,995.82% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | 20,813.57% | ๐ฎ๐ฑ Israel |